HER2-enriched tumors account for a high proportion of early stage HER2-positive breast cancers and have been associated with improved likelihood of pCR following HER2-based neoadjuvant therapy [[3], [4], [5]]. This evidence concerns the gene ERBB2 and breast carcinoma.